Luna Bioscience develops solutions to emerging global infectious diseases. Candidates use novel genomics technology to yield diverse vaccine & therapeutic delivery methods including recombinant proteins and biologics. We're addressing huge unmet needs starting with the $1Bn animal leptospirosis market, for which our vaccine candidate has 2 in vivo POCs. We'll license and/or sell assets to global animal/human pharma firms - we're under NDA with 4.